Rudi Bao

Summary

Affiliation: Curis Inc
Country: USA

Publications

  1. ncbi CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy
    Rudi Bao
    Curis, Inc, Cambridge, Massachusetts 02138, USA
    Clin Cancer Res 15:4046-57. 2009
  2. ncbi Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer
    Rudi Bao
    Oncology, Curis, Inc, 45 Moulton Street, Cambridge, MA 02138, USA
    Mol Cancer Ther 8:3296-306. 2009
  3. ncbi Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer
    Xiong Cai
    Curis Inc, 45 Moulton Street, Cambridge, Massachusetts 02138, USA
    J Med Chem 53:2000-9. 2010
  4. ncbi CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity
    Cheng Jung Lai
    Curis, Inc, Cambridge, Massachusetts, USA
    Cancer Res 70:3647-56. 2010

Collaborators

  • Jing Wang
  • Xiong Cai
  • Cheng Jung Lai
  • Ling Yin
  • Mitchell Keegan
  • Xu Tao
  • Da Gong Wang
  • Maria Samson
  • William E Munger
  • Changgeng Qian
  • Jeffrey Forrester
  • Carmen V Pepicelli
  • Brian Zifcak
  • Steven DellaRocca
  • Ruzanna Atoyan
  • Guang Xin Xu
  • Hui Qu
  • Hai Xiao Zhai

Detail Information

Publications4

  1. ncbi CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy
    Rudi Bao
    Curis, Inc, Cambridge, Massachusetts 02138, USA
    Clin Cancer Res 15:4046-57. 2009
    ..We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class. Here, we report its unique pharmacologic properties and antitumor activities in a variety of tumor types...
  2. ncbi Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer
    Rudi Bao
    Oncology, Curis, Inc, 45 Moulton Street, Cambridge, MA 02138, USA
    Mol Cancer Ther 8:3296-306. 2009
    ..These results suggest that CUDC-305 holds promise for the treatment of NSCLC with primary or acquired resistance to EGFR inhibitor therapy...
  3. ncbi Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer
    Xiong Cai
    Curis Inc, 45 Moulton Street, Cambridge, Massachusetts 02138, USA
    J Med Chem 53:2000-9. 2010
    ....
  4. ncbi CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity
    Cheng Jung Lai
    Curis, Inc, Cambridge, Massachusetts, USA
    Cancer Res 70:3647-56. 2010
    ..Cancer Res; 70(9); 3647-56. (c)2010 AACR...